Business
Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS
SIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has been limited by the
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nSIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has been limited by the performance of conventional whole-body MR systems thus far.\n\n\n\nThis system is designed to advance MR research in complex imaging procedures in neurology, oncology & psychiatry.\n\n\n\n CHICAGO--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR systems. Neuroscience, particularly in the study of psychiatric diseases and neurological disorders such as Alzheimer’s, has been constrained by technological and biological limitations, leaving many aspects of the brain structure and functionality largely unexplored.\n\n\nToday, 43% of the world’s population suffer from neurological disordersii, yet only a fraction can be diagnosed by MRI, making the need to expand the neurological clinical applications of MRI critical. SIGNA MAGNUS represents GE HealthCare’s vision of our most advanced 3.0T MR imaging device, specifically designed for the highest standards of neurological and oncological research for head-only imaging. SIGNA MAGNUS stands at the pinnacle of MR excellence, designed to offer detail and clarity that allows for an in-depth exploration of brain microstructure, microvasculature, and function. Through SIGNA MAGNUS, GE HealthCare will help to empower neuroscientists, neurologists, neuroradiologists and oncologists to transcend barriers, with the goal of enhancing the diagnosis, understanding, and treatment of complex diseases.\n\n\n\"With SIGNA MAGNUS, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care,” said Kelly Londy, CEO, MR GE HealthCare.\n\n\n“This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what's possible in MR imaging. The potential impact of SIGNA MAGNUS on patient outcomes and our understanding of the human brain is profound.\"\n\n\nThis advanced system offers superior gradient performance with its HyperG gradient technology, featuring 300 mT/m and 750 T/m/s, enabling the detec...